Population pharmacokinetics of nintedanib in patients with idiopathic pulmonary fibrosis

Pulmonary Pharmacology and Therapeutics

Volumn 48, Issue , 2018, Pages 136-143

  Schmid, Ulrike ^a   Doege, Christiane ^a   Dallinger, Claudia ^a   Freiwald, Matthias ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Covariates; Idiopathic pulmonary fibrosis; Nintedanib; Population pharmacokinetics

Indexed keywords

LACTATE DEHYDROGENASE; NINTEDANIB; INDOLE DERIVATIVE; PROTEIN KINASE INHIBITOR;

ABSORPTION LAG TIME; ABSORPTION RATE CONSTANT; AGE; AGED; AREA UNDER THE CURVE; ARTICLE; ASIAN; BODY WEIGHT; COMPARTMENT MODEL; CONCENTRATION AT STEADY-STATE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXPOSURE; ETHNIC GROUP; FEMALE; FIBROSING ALVEOLITIS; FIRST ORDER RATE CONSTANT; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PHARMACOKINETIC PARAMETERS; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; SMOKING; VOLUME OF DISTRIBUTION AT STEADY-STATE; BIOLOGICAL MODEL; BLOOD; META ANALYSIS; MIDDLE AGED; NONLINEAR SYSTEM; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); TISSUE DISTRIBUTION;

AGED; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INDOLES; L-LACTATE DEHYDROGENASE; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NONLINEAR DYNAMICS; PROTEIN KINASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TISSUE DISTRIBUTION;

EID: 85034025564     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2017.11.004     Document Type: Article

References (30)

1. Hilberg, F., Roth, G.J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., Heckel, A., Rettig, W.J., BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 68:12 (2008), 4774–4782.
2. Wollin, L., Wex, E., Pautsch, A., Schnapp, G., Hostettler, K.E., Stowasser, S., Kolb, M., Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur. Respir. J. 45:5 (2015), 1434–1445.
3. Roth, G.J., Binder, R., Colbatzky, F., Dallinger, C., Schlenker-Herceg, R., Hilberg, F., Wollin, S.L., Kaiser, R., Nintedanib: from discovery to the clinic. J. Med. Chem. 58:3 (2015), 1053–1063.
4. McCormack, P.L., Nintedanib: first global approval. Drugs 75:1 (2015), 129–139.
5. Selman, M., King, T.E., Pardo, A., Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann. Intern Med. 134:2 (2001), 136–151.
6. Wollin, L., Maillet, I., Quesniaux, V., Holweg, A., Ryffel, B., Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis. J. Pharmacol. Exp. Ther. 349:2 (2014), 209–220.
7. ® (Nintedanib) Capsules, for Oral Use; Prescribing Information, Revised: 08/2017. 2017 Retrieved from http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Ofev/ofev.pdf. (Accessed 29 August 2017)
8. European Medicines Agency, Ofev. Summary of Product Characteristics. February 2017 Retrieved from http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003821/WC500182474.pdf version 14. (Accessed 29 August 2017)
9. Bouquet, C., Lamande, N., Brand, M., Gasc, J.M., Jullienne, B., Faure, G., Griscelli, F., Opolon, P., Connault, E., Perricaudet, M., Corvol, P., Suppression of angiogenesis, tumor growth, and metastasis by adenovirus-mediated gene transfer of human angiotensinogen. Mol. Ther. 14:2 (2006), 175–182.
10. Reck, M., Kaiser, R., Mellemgaard, A., Douillard, J.Y., Orlov, S., Krzakowski, M., von Pawel, J., Gottfried, M., Bondarenko, I., Liao, M., Gann, C.N., Barrueco, J., Gaschler-Markefski, B., Novello, S., Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol. 15:2 (2014), 143–155.
11. Hanna, N.H., Kaiser, R., Sullivan, R.N., Aren, O.R., Ahn, M.J., Tiangco, B., Voccia, I., Pawel, J.V., Kovcin, V., Agulnik, J., Gaschler-Markefski, B., Barrueco, J., Sikken, P., Schloss, C., Kim, J.H., Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): a randomized, double-blind, phase III trial. Lung Cancer 102 (2016), 65–73.
12. European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP) Assessment Report for Vargatef (Nintedanib)., 25 September 2014 Retrieved from http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002569/WC500179972.pdf. (Accessed 29 August 2017)
13. Ogura, T., Taniguchi, H., Azuma, A., Inoue, Y., Kondoh, Y., Hasegawa, Y., Bando, M., Abe, S., Mochizuki, Y., Chida, K., Kluglich, M., Fujimoto, T., Okazaki, K., Tadayasu, Y., Sakamoto, W., Sugiyama, Y., Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis. Eur. Respir. J. 45:5 (2015), 1382–1392.
14. Dallinger, C., Trommeshauser, D., Marzin, K., Liesener, A., Kaiser, R., Stopfer, P., Pharmacokinetic properties of nintedanib in healthy volunteers and patients with advanced cancer. J. Clin. Pharmacol. 56:11 (2016), 1387–1394.
15. Stopfer, P., Rathgen, K., Bischoff, D., Ludtke, S., Marzin, K., Kaiser, R., Wagner, K., Ebner, T., Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers. Xenobiotica 41:4 (2011), 297–311.
16. European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP) Assessment Report for Ofev (Nintedanib)., 20 November 2014 Retrieved from http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/003821/WC500182476.pdf. (Accessed 29 August 2017)
17. Schmid, U., Liesenfeld, K.H., Fleury, A., Dallinger, C., Freiwald, M., Population pharmacokinetics of nintedanib, an angiokinase inhibitor, in patients with non-small cell lung cancer or idiopathic pulmonary fibrosis. Cancer Chemother. Pharmacol., 2017, 10.1007/s00280-017-3452-0 Epub ahead of print.
18. Richeldi, L., Costabel, U., Selman, M., Kim, D.S., Hansell, D.M., Nicholson, A.G., Brown, K.K., Flaherty, K.R., Noble, P.W., Raghu, G., Brun, M., Gupta, A., Juhel, N., Kluglich, M., du Bois, R.M., Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N. Engl. J. Med. 365:12 (2011), 1079–1087.
19. Richeldi, L., du Bois, R.M., Raghu, G., Azuma, A., Brown, K.K., Costabel, U., Cottin, V., Flaherty, K.R., Hansell, D.M., Inoue, Y., Kim, D.S., Kolb, M., Nicholson, A.G., Noble, P.W., Selman, M., Taniguchi, H., Brun, M., Le, M.F., Girard, M., Stowasser, S., Schlenker-Herceg, R., Disse, B., Collard, H.R., INPULSIS Trial Investigators, Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N. Engl. J. Med. 370:22 (2014), 2071–2082.
20. Raghu, G., Collard, H.R., Egan, J.J., Martinez, F.J., Behr, J., Brown, K.K., Colby, T.V., Cordier, J.F., Flaherty, K.R., Lasky, J.A., Lynch, D.A., Ryu, J.H., Swigris, J.J., Wells, A.U., Ancochea, J., Bouros, D., Carvalho, C., Costabel, U., Ebina, M., Hansell, D.M., Johkoh, T., Kim, D.S., King, T.E. Jr., Kondoh, Y., Myers, J., Muller, N.L., Nicholson, A.G., Richeldi, L., Selman, M., Dudden, R.F., Griss, B.S., Protzko, S.L., Schunemann, H.J., ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis., an official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 183:6 (2011), 788–824.
21. Lindbom, L., Ribbing, J., Jonsson, E.N., Perl-speaks-NONMEM (PsN)–a Perl module for NONMEM related programming. Comput. Methods Programs Biomed. 75:2 (2004), 85–94.
22. Lindbom, L., Pihlgren, P., Jonsson, E.N., PsN-Toolkit–a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput. Methods Programs Biomed. 79:3 (2005), 241–257.
23. Yardley, D.A., Proactive management of adverse events maintains the clinical benefit of ixabepilone. Oncologist 14:5 (2009), 448–455.
24. Bristol-Myers Squibb, Ixempra Kit (Ixabepilone) for Injection, for Intravenous Infusion Only. Prescribing Information, Revised: 01/2016. 2016 Retrieved from http://ixempra.com/downloads/full_pi.pdf. (Accessed 29 August 2017)
25. LoRusso, P.M., Venkatakrishnan, K., Ramanathan, R.K., Sarantopoulos, J., Mulkerin, D., Shibata, S.I., Hamilton, A., Dowlati, A., Mani, S., Rudek, M.A., Takimoto, C.H., Neuwirth, R., Esseltine, D.L., Ivy, P., Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432. Clin. Cancer Res. 18:10 (2012), 2954–2963.
26. U.S.Food and Drug Administration, Guidance for Industry: Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling. May 2003, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER) Retrieved from https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072123.pdf. (Accessed 29 August 2017)
27. Synold, T.W., Takimoto, C.H., Doroshow, J.H., Gandara, D., Mani, S., Remick, S.C., Mulkerin, D.L., Hamilton, A., Sharma, S., Ramanathan, R.K., Lenz, H.J., Graham, M., Longmate, J., Kaufman, B.M., Ivy, P., Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group study. Clin. Cancer Res. 13:12 (2007), 3660–3666.
28. Cockcroft, D.W., Gault, M.H., Prediction of creatinine clearance from serum creatinine. Nephron 16:1 (1976), 31–41.
29. Bergstrand, M., Hooker, A.C., Wallin, J.E., Karlsson, M.O., Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 13:2 (2011), 143–151.
30. Marzin, K., Kretschmar, G., Luedtke, D., Kraemer, S., Kuelzer, R., Schlenker-Herceg, R., Schmid, U., Schnell, D., Dallinger, C., Pharmacokinetics of nintedanib in subjects with hepatic impairment. J. Clin. Pharmacol., 2017, 10.1002/jcph.1025 Epub ahead of print.